| Literature DB >> 25521977 |
Senthilkumar Sankararaman1, Majed Jeroudi1, Hassan Ibrahim1.
Abstract
Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening condition characterized by thrombotic microangiopathy. The standard treatment for TTP is plasmapheresis. For refractory or relapsing cases, various immunosuppressive agents have been tried, and among them rituximab has shown promising results. TTP is rarer in the pediatric age group and the use of rituximab in children with TTP is limited. Reported herein is the successful treatment of relapsing autoimmune TTP with rituximab in a 12-year-old girl.Entities:
Keywords: ADAMTS13 deficiency; plasma exchange; plasmapheresis; relapse; rituximab; thrombocytopenia; thrombotic thrombocytopenic purpura
Mesh：
Substances：
Year: 2014 PMID： 25521977 DOI： 10.1111/ped.12344
Source DB: PubMed Journal: Pediatr Int ISSN： 1328-8067 Impact factor: 1.524